CO6670586A2 - Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina - Google Patents

Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina

Info

Publication number
CO6670586A2
CO6670586A2 CO13026634A CO13026634A CO6670586A2 CO 6670586 A2 CO6670586 A2 CO 6670586A2 CO 13026634 A CO13026634 A CO 13026634A CO 13026634 A CO13026634 A CO 13026634A CO 6670586 A2 CO6670586 A2 CO 6670586A2
Authority
CO
Colombia
Prior art keywords
naphthalenyl
pyrazol
oxy
ethyl
methyl
Prior art date
Application number
CO13026634A
Other languages
English (en)
Inventor
Jordi Benet Buchholz
Laura Puig Fernandez
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of CO6670586A2 publication Critical patent/CO6670586A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas sólidas que tienen un bajo grado de cristalinidad o la sal de hidrocloruro de casi amorfa de 4 - [2 - [[5-metil-1-(2-naftalenil)-1H-pirazol-3-il] oxi] etil] morfolina (P027) y métodos para su preparación.
CO13026634A 2010-08-09 2013-02-08 Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina CO6670586A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382225A EP2426111A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms

Publications (1)

Publication Number Publication Date
CO6670586A2 true CO6670586A2 (es) 2013-05-15

Family

ID=43244877

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13026634A CO6670586A2 (es) 2010-08-09 2013-02-08 Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina

Country Status (19)

Country Link
US (1) US9428462B2 (es)
EP (2) EP2426111A1 (es)
JP (1) JP5899214B2 (es)
KR (1) KR20130095751A (es)
CN (1) CN103052626B (es)
AR (1) AR082608A1 (es)
AU (1) AU2011288550A1 (es)
BR (1) BR112013002651A2 (es)
CA (1) CA2807855C (es)
CO (1) CO6670586A2 (es)
ES (1) ES2543429T3 (es)
HK (1) HK1186468A1 (es)
MA (1) MA34512B1 (es)
MX (1) MX341711B (es)
PT (1) PT2603495E (es)
RU (1) RU2013110313A (es)
SG (1) SG187745A1 (es)
TW (1) TW201219387A (es)
WO (1) WO2012019984A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
CA2933511A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations
JP2017503765A (ja) 2013-12-17 2017-02-02 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ガバペンチノイドおよびシグマ受容体の組み合わせ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04364129A (ja) * 1990-10-26 1992-12-16 Asahi Chem Ind Co Ltd ６−置換アルコキシキノキサリン誘導体含有医薬組成物およびその製造法
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
ES2396421T3 (es) * 2004-08-27 2013-02-21 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma
CA2576144C (en) * 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2292236A1 (en) * 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2361904A1 (en) 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP2335688A1 (en) * 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
RU2559325C2 (ru) * 2009-11-25 2015-08-10 Лабораторьос Дель Др. Эстеве, С.А. Соли 4-[2-[[5-метил-1-(2-нафталинил)-1н-пиразол-3-ил]окси]этил]морфолина
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
ES2586212T3 (es) * 2010-02-04 2016-10-13 Laboratorios Del Dr. Esteve, S.A. Polimorfos y solvatos de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etil]morfolina
EP2426112A1 (en) 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP2388005A1 (en) * 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain

Also Published As

Publication number Publication date
US9428462B2 (en) 2016-08-30
AR082608A1 (es) 2012-12-19
CN103052626A (zh) 2013-04-17
WO2012019984A1 (en) 2012-02-16
EP2603495A1 (en) 2013-06-19
EP2426111A1 (en) 2012-03-07
BR112013002651A2 (pt) 2016-05-31
ES2543429T3 (es) 2015-08-19
KR20130095751A (ko) 2013-08-28
US20130150575A1 (en) 2013-06-13
CA2807855C (en) 2018-10-23
JP5899214B2 (ja) 2016-04-06
CA2807855A1 (en) 2012-02-16
EP2603495B1 (en) 2015-05-06
CN103052626B (zh) 2017-06-06
MA34512B1 (fr) 2013-09-02
TW201219387A (en) 2012-05-16
RU2013110313A (ru) 2014-09-20
MX341711B (es) 2016-08-31
AU2011288550A1 (en) 2013-02-21
HK1186468A1 (en) 2014-03-14
PT2603495E (pt) 2015-08-28
JP2013533298A (ja) 2013-08-22
MX2013001559A (es) 2013-03-07
SG187745A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CO6670586A2 (es) Formas solidas de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina
CY2019013I1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI1007927A2 (pt) instrumento de grampeamento cirúrgico
BRPI0822560A2 (pt) Instrumento para aplicações endoscópicas ou semelhantes
ECSP12012039A (es) Polimorfos y solvatos de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina
SV2009003392A (es) Aril pirrolidinas insecticidas
BRPI1009112A2 (pt) inibidores de tirosina quinase de bruton
BR112013016141A2 (pt) cartucho para armazenamento de instrumentos médicos
BR112012004448A2 (pt) "compostos e composições como inibidores de proteína cinase"
ECSP12011959A (es) SALES DE 4-[2-[[5-METIL-1-(2-NAFTALENIL)-1H-PIRAZOL-3-il]OXI]ETIL]MORFOLINA
PT2605714T (pt) Conjunto cirúrgico de instrumentos para incisão de precisão
DK2343981T3 (da) Glyphosatformuleringer indeholdende amidoalkylamin-tensider
PL2503993T3 (pl) Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1H-pirazol-3-ilo]oksy]etylo]morfoliny
BRPI0718548A2 (pt) Estabilização de vacinas por liofilização
BRPI0917815A2 (pt) Combinação herbicida que contém difluormetano sulfonilanilidas substituídas por dimetoxitriazilina
BRPI1009984A2 (pt) "válvula de diafragma"
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
DK3251508T3 (da) Alkoholalkoxylater som adjuvanser til agrokemiske formuleringer
BRPI0807967A2 (pt) Partículas micronizadas estabilizadas
BR112012014449A2 (pt) composições biocidas que compreendem derivados do ácido piroglutâmico
IN2014CN00981A (es)
BR112013000506A2 (pt) núcleo absorvente
BR112012033437A2 (pt) núcleo absorvente
FR2949315B1 (fr) Instrument chirurgical

Legal Events

Date Code Title Description
FA Application withdrawn